<DOC>
	<DOCNO>NCT01377324</DOCNO>
	<brief_summary>The dose fulvestrant optimally downregulate estrogen receptor ( ER ) currently subject debate . Effects fulvestrant ERs may evaluable molecular image use positron emission tomography ER-specific FES tracer . In pilot study evaluate effect new dose fulvestrant ( 500mg i.m . ) availability ER binding sit 15 metastatic breast cancer patient .</brief_summary>
	<brief_title>Molecular Imaging Fulvestrant Effects Availability ER Binding Sites</brief_title>
	<detailed_description>The estrogen receptor ( ER ) express approximately 70 % breast carcinoma . In patient signal via ER induces proliferation cell survival malignant cell . Fulvestrant inhibit signal route block receptor decrease ER-expression increase turn-over rate . The historical standard dose fulvestrant 250mg every 28 day i.m . ; however study perform serial biopsy show ER-downregulation suboptimal . Recently standard dose set 500mg i.m . day 1 ; 14 ; 28 every 28 day thereafter . Although slightly effective 250mg dose , still question remain respect require dose establish maximal downregulation ER-signaling . Immunohistochemistry provide static information , i.e . level ER-expression . However , dynamic information evaluate effect fulvestrant occupancy ERs , may also valuable . Whole-body imaging availability ER binding site use FES-PET may prove valuable evaluate effect fulvestrant ER non-invasively individual patient . This potentially allow adjustment dose individual patient aid therapy efficacy . In pilot-study evaluate 15 metastatic breast cancer patient . All patient undergo FES-PET/CT baseline , FES-PET 1 month , FES-PET/CT three month . Hormone- fulvestrant level measure patient . Whenever possible , tumor biopsy perform correlate FES-PET result .</detailed_description>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1 . Patients history histological proven ERpositive primary breast cancer , whenever available , histological proven ERpositive recurrence . 2 . Postmenopausal status ( age ≥ 45 year amenorrhea &gt; 12 month prior bilateral ovariectomy 3 . Documentation negative pregnancy test must available woman le 2 year menopause 4 . Progressive disease 2 line hormonal therapy 5 . No previous fulvestrant treatment 6 . ERantagonists discontinue 5 week prior FESPET prevent false negative FESPET result . The use aromatase inhibitor allow 7 . ECOG performance status 0 , 1 2 8 . Life expectancy &gt; 3 month 9 . Creatinine clearance ≥ 30 ml/min 10 . Age ≥ 18 year 11 . Signed write informed consent 12 . Able comply protocol 1 . Evidence central nervous system metastases 2 . Presence lifethreatening visceral metastasis 3 . &gt; 3 line endocrine therapy metastatic disease 4 . &gt; 2 line chemotherapy metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>FES</keyword>
	<keyword>PET</keyword>
	<keyword>Positron</keyword>
	<keyword>Emission</keyword>
	<keyword>Tomography</keyword>
	<keyword>Fluoroestradiol</keyword>
	<keyword>FES-PET</keyword>
	<keyword>Molecular Imaging</keyword>
	<keyword>Estrogen Receptor</keyword>
</DOC>